[Immunity state of oncological patients during long-term treatment with tramal].
Narcotic analgesics have an inhibiting effect on the immunity and that is why their use for pain relief in cancer patients cannot be regarded as adequate. The effect of a new synthetic analgesic tramal (tramal hydrochloride) on the immune system has been studied. Cellular immunity indexes, immunoglobulin level, and phagocytic activity of neutrophils have been determined before treatment and 1 and 2 weeks after the treatment started. The data obtained have shown that tramal does not inhibit the immune system. It has been also noted that pain relief in cancer patients improved the indexes of cellular and humoral immunity.
Novikov
Iu A
IuA
Kon'kov
Sh Kh
ShKh
Shumilov
E I
EI
D000328:Adult; D000368:Aged; D000917:Antibody Formation; D006801:Humans; D007111:Immunity, Cellular; D007414:Intestinal Neoplasms / Q000276:immunology; D007420:Intestine, Large; D007822:Laryngeal Neoplasms / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology*; D009959:Oropharyngeal Neoplasms / Q000276:immunology; D012004:Rectal Neoplasms / Q000276:immunology; D012509:Sarcoma / Q000276:immunology; D012983:Soft Tissue Neoplasms / Q000276:immunology; D013274:Stomach Neoplasms / Q000276:immunology; D013997:Time Factors; D014147:Tramadol / Q000008:administration & dosage / Q000494:pharmacology*; D001749:Urinary Bladder Neoplasms / Q000276:immunology
D014147:Tramadol
Sostoianie immuniteta u onkologicheskikh bol'nykh pri dlitel'nom primenenii tramala.